S. 1954 · 119th Congress (2025–2027)
Biosimilar Red Tape Elimination Act
This bill deems all biosimilars licensed by the Food and Drug Administration (FDA) interchangeable with their reference products.
A biosimilar is a biological product (e.g., a drug or vaccine) that is very similar to a brand-name biological product (i.e., the reference product). Under current law, a biosimilar that meets additional requirements may be deemed interchangeable with the reference product; this designation allows pharmacists to substitute the interchangeable biosimilar when filling a prescription for the reference product, depending on state law. Further, the first biosimilar deemed interchangeable with a given reference product is awarded a period of marketing exclusivity.
The bill eliminates additional requirements for demonstrating interchangeability so that all licensed biosimilars are deemed interchangeable with their reference products. (Draft guidance released by the FDA in 2024 proposed to make some of these interchangeability requirements optional, including studies related to the safety of switching between use of the biosimilar and reference product. It has not been finalized.)
This change takes effect 60 days after the bill is enacted, and previously licensed biosimilars must be deemed interchangeable with their reference products on that date. However, the bill preserves the exclusivity period for first interchangeable biosimilars licensed before the bill’s enactment. For example, if a new biosimilar licensed after the bill takes effect relies on the same reference product as an existing biosimilar that is subject to an unexpired exclusivity period, the new biosimilar is not deemed interchangeable with the reference product until the exclusivity period has ended.
Show official title
A bill to improve the requirements for making a determination of interchangeability of a biological product and its reference product.
Reported
This bill’s path
This is S. 1954’s recorded path, not a universal congressional workflow.
How bills become lawAll actionsIntroduced
Passed Senate
Passed House
Sent to President
Signed into law
- Sponsor
- Sen. Mike Lee (R-UT)
- Cosponsors
5 cosponsors
3 original · 2 later
- Sen. Margaret Wood Hassan (D-NH)· Original · Jun 4, 2025
- Sen. Ben Ray Luján (D-NM)· Original · Jun 4, 2025
- Sen. Rand Paul (R-KY)· Original · Jun 4, 2025
- Sen. Eric Schmitt (R-MO)· Later · Jun 24, 2025
- Sen. Jon Ossoff (D-GA)· Later · Jun 16, 2026
- Policy area
- Health
- Subjects
- Drug safety, medical device, and laboratory regulation
- Government information and archives
- Licensing and registrations
- Prescription drugs
On this page
Timeline
i
In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.
Introduced in Senate
Document: Introduced in Senate
Sources
- Congress.gov action
- Library of Congress
- Latest
▸ 3 committee actions · Jun 4, 2025 – Jul 27, 2026
Referred to committee
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Sources
- Congress.gov action
- Senate
Ordered reported
Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.
Sources
- Congress.gov action
- Senate
Reported by committee
Committee on Health, Education, Labor, and Pensions. Reported by Senator Cassidy with an amendment in the nature of a substitute. Without written report.
Sources
- Congress.gov action
- Senate
Committees
- SenateHealth, Education, Labor, and PensionsReferred Jun 4, 2025 · Markup Jun 17, 2026 · Reported Jul 27, 2026
Jun 17, 2026 · Open business meeting
Text & titles
i
Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.
Titles (2)
Biosimilar Red Tape Elimination Act
Short title, Display title · Reported to Senate, Introduced in Senate
A bill to improve the requirements for making a determination of interchangeability of a biological product and its reference product.
Official title · Introduced in Senate